RESUMO
OBJECTIVE: This pilot study assessed the feasibility, efficacy and safety of an individual dose-titration approach, and of the intravenous (IV), intramuscular (IM) and subcutaneous (SC) routes for treating depression with ketamine. METHOD: Fifteen treatment-refractory depressed participants received ketamine or midazolam (control treatment) in a multiple crossover, double-blind study. Ketamine was administered by IV (n = 4), IM (n = 5) or SC (n = 6) injection. Dose titration commenced at 0.1 mg/kg, increasing by 0.1 mg/kg up to 0.5 mg/kg, given in separate treatment sessions separated by ≥1 week, with one placebo control treatment randomly inserted. Mood, psychotomimetic and hemodynamic effects were assessed and plasma ketamine concentrations assayed. RESULTS: Twelve participants achieved response and remission criteria, achieved at doses as low as 0.1 mg/kg. All three routes of administration resulted in comparable antidepressant effects. Fewest adverse effects were noted with the SC route. Antidepressant response, adverse effects and ketamine concentrations were dose-related. CONCLUSION: Antidepressant response occurred at a range of doses and at <0.5 mg/kg. The dose-titration approach is a practical method for optimizing the efficacy - side-effects trade-off on an individual patient basis. This pilot study provides preliminary evidence for SC injection as a practical, feasible and efficacious treatment approach.
Assuntos
Antidepressivos/administração & dosagem , Transtorno Depressivo/tratamento farmacológico , Ketamina/administração & dosagem , Administração Intravenosa , Adulto , Estudos Cross-Over , Transtorno Depressivo/psicologia , Relação Dose-Resposta a Droga , Método Duplo-Cego , Estudos de Viabilidade , Feminino , Humanos , Injeções Intramusculares , Injeções Subcutâneas , Masculino , Pessoa de Meia-Idade , Projetos Piloto , Escalas de Graduação Psiquiátrica , Resultado do TratamentoRESUMO
BACKGROUND: There is conjecture regarding the profile of cognitive development over time in children with Down syndrome (DS). Characterising this profile would be valuable for the planning and assessment of intervention studies. METHOD: A systematic search of the literature from 1990 to the present was conducted to identify longitudinal data on cognitive trajectories in children with DS. RESULTS: Thirteen studies were identified: six assessed overall cognitive performance and seven assessed specific cognitive domains. Studies assessing IQ reported a decline across time. Studies assessing change in cognitive domains were, for the most part, not interpretable because of large age ranges in samples obscuring age-specific data. CONCLUSION: The current literature has only begun to describe typical cognitive developmental trajectories in children with DS; additional research is needed to clarify this topic.
Assuntos
Desenvolvimento Infantil/fisiologia , Cognição/fisiologia , Síndrome de Down/fisiopatologia , Síndrome de Down/terapia , Criança , Humanos , Fatores de TempoRESUMO
Psychiatric disorders can often be viewed as extremes of personality traits. The primary action of drugs that ameliorate these disorders may, thus, be to alter the patient's position on a relevant trait dimension. Here, we suggest that interactions between such trait dimensions may also be important for disorder. Internalizing disorders show important differences in terms of range of activity and speed of response of medications. Established antidepressant and anxiolytic medications are slow in onset and have differing effects across different internalizing disorders. In contrast, low-dose ketamine is rapidly effective and improves symptom ratings in all internalizing disorders. To account for this, we propose a "double hit" model for internalizing disorders: generation (and maintenance) require two distinct forms of neural dysfunction to coincide. One hit, sensitive to ketamine, is disorder-general: dysfunction of a neural system linked to high levels of the personality trait of neuroticism. The other hit is disorder-specific: dysfunction of one of a set of disorder-specific neural modules, each with its own particular pattern of sensitivity to conventional drugs. Our hypothesis applies only to internalizing disorders. So, we predict that ketamine will be effective in simple phobia and (perhaps partially) in anorexia nervosa, but would make no such prediction about other disorders where neuroticism might also be important secondarily (e.g. attention deficit hyperactivity disorder and schizophrenia).
RESUMO
The objective of our study was to determine the QTc effects of tolterodine. A crossover-design thorough QT study of recommended (2 mg twice daily) and supratherapeutic (4 mg twice daily) doses of tolterodine, moxifloxacin (400 mg once daily), and placebo was performed. Electrocardiograms (ECGs) and pharmacokinetic samples were obtained on days 1-4; time-matched baseline ECGs were taken on day 0. Mean placebo-subtracted change from baseline Fridericia-corrected QT (QTcF) during peak drug exposure on day 4 was the primary end point. Mean QTcF prolongation of moxifloxacin was 8.9 ms (machine-read) and 19.3 ms (manual-read). At recommended and supratherapeutic tolterodine doses, mean QTcF prolongation was 1.2 and 5.6 ms (machine-read), respectively, and 5.0 and 11.8 ms (manual-read), respectively. The QTc effect of tolterodine was lower than moxifloxacin. No subject receiving tolterodine exceeded the clinically relevant thresholds of 500 ms absolute QTc or 60 ms change from baseline. In conclusion, tolterodine does not have a clinically significant effect on QT interval.
Assuntos
Compostos Benzidrílicos/administração & dosagem , Cresóis/administração & dosagem , Eletrocardiografia/efeitos dos fármacos , Antagonistas Muscarínicos/administração & dosagem , Fenilpropanolamina/administração & dosagem , Adulto , Antibacterianos/farmacocinética , Área Sob a Curva , Compostos Aza/farmacocinética , Compostos Benzidrílicos/efeitos adversos , Cresóis/efeitos adversos , Estudos Cross-Over , Citocromo P-450 CYP2D6/genética , Citocromo P-450 CYP2D6/metabolismo , Método Duplo-Cego , Feminino , Fluoroquinolonas , Genótipo , Frequência Cardíaca/efeitos dos fármacos , Humanos , Masculino , Pessoa de Meia-Idade , Modelos Estatísticos , Moxifloxacina , Antagonistas Muscarínicos/efeitos adversos , Fenilpropanolamina/efeitos adversos , Quinolinas/farmacocinética , Tartarato de TolterodinaRESUMO
The low productivity and escalating costs of drug development have been well documented over the past several years. Less than 10% of new compounds that enter clinical trials ultimately make it to the market, and many more fail in the preclinical stages of development. These challenges in the "critical path" of drug development are discussed in a 2004 publication by the US Food and Drug Administration. The document emphasizes new tools and various opportunities to improve drug development. One of the opportunities recommended is the application of "model-based drug development (MBDD)." This paper discusses what constitutes the key elements of MBDD and how these elements should fit together to inform drug development strategy and decision-making.
Assuntos
Ensaios Clínicos como Assunto/métodos , Relação Dose-Resposta a Droga , Aprovação de Drogas , Desenho de Fármacos , Modelos Biológicos , Farmacologia , Projetos de Pesquisa , Doença de Alzheimer/tratamento farmacológico , Doença de Alzheimer/psicologia , Aminas/farmacologia , Aminas/uso terapêutico , Analgésicos/farmacologia , Analgésicos/uso terapêutico , Animais , Anticolesterolemiantes/farmacologia , Anticolesterolemiantes/uso terapêutico , Compostos Bicíclicos Heterocíclicos com Pontes/farmacologia , Compostos Bicíclicos Heterocíclicos com Pontes/uso terapêutico , Caproatos/farmacologia , Caproatos/uso terapêutico , Colesterol/sangue , Ensaios Clínicos como Assunto/legislação & jurisprudência , Ensaios Clínicos como Assunto/estatística & dados numéricos , Cognição/efeitos dos fármacos , Simulação por Computador , Ácidos Cicloexanocarboxílicos/farmacologia , Ácidos Cicloexanocarboxílicos/uso terapêutico , Gabapentina , Glicoproteínas/farmacologia , Glicoproteínas/uso terapêutico , Guias como Assunto , Humanos , Inibidores de Hidroximetilglutaril-CoA Redutases/farmacologia , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Hipercolesterolemia/sangue , Hipercolesterolemia/tratamento farmacológico , Fatores Imunológicos/farmacologia , Fatores Imunológicos/uso terapêutico , Metanálise como Assunto , Modelos Estatísticos , Agonistas Muscarínicos/farmacologia , Agonistas Muscarínicos/uso terapêutico , Neuralgia Pós-Herpética/tratamento farmacológico , Infiltração de Neutrófilos/efeitos dos fármacos , Oximas/farmacologia , Oximas/uso terapêutico , Farmacocinética , Reprodutibilidade dos Testes , Acidente Vascular Cerebral/tratamento farmacológico , Acidente Vascular Cerebral/imunologia , Estados Unidos , United States Food and Drug Administration , Ácido gama-Aminobutírico/farmacologia , Ácido gama-Aminobutírico/uso terapêuticoRESUMO
The possibility that panic disorder might be due to abnormal activity of endogenous ligands of the benzodiazepine receptor was investigated with the use of the benzodiazepine antagonist flumazenil. Physiological and subjective psychological responses to this selective antagonist were measured in 10 patients with panic disorder and in 10 control subjects, by using a placebo-controlled crossover study design. Subjective anxiety responses after flumazenil infusion were significantly higher in the patient group with panic disorder than in the controls, and eight patients with panic disorder but no controls had panic attacks. This anxiogenic effect of flumazenil in the patients argues against the presence of endogenous anxiogenic (inverse agonist) ligands. Possible explanations include the differential production of an anxiolytic endogenous ligand or an altered benzodiazepine receptor "set-point." Such an abnormality may contribute to the pathogenesis of panic disorder.
Assuntos
Transtornos de Ansiedade/induzido quimicamente , Flumazenil/farmacologia , Pânico , Receptores de GABA-A/efeitos dos fármacos , Adolescente , Adulto , Transtornos de Ansiedade/fisiopatologia , Transtornos de Ansiedade/psicologia , Pressão Sanguínea/efeitos dos fármacos , Método Duplo-Cego , Feminino , Flumazenil/administração & dosagem , Frequência Cardíaca/efeitos dos fármacos , Humanos , Infusões Intravenosas , Ligantes , Masculino , Placebos , Receptores de GABA-A/fisiologiaRESUMO
BACKGROUND: The subjective and reinforcing effects of cocaine in humans are associated with the enhancement of endogenous dopamine function in the mesolimbic system. This study examined the role of dopamine D1-like receptors in the behavioral and mood effects of cocaine by evaluating the effects of the selective D1/D5 antagonist ecopipam (SCH 39166) on subjective responses to intravenous cocaine in 11 subjects with cocaine dependence as defined by DSM-IV. METHODS: Subjects were pretreated in a randomized double-blind fashion with either placebo or 10 mg, 25 mg, or 100 mg of ecopipam orally on 4 separate occasions. Two hours later a single intravenous injection of 30 mg of cocaine was administered. Subjective and cardiovascular responses were measured and blood samples for pharmacokinetic evaluation were obtained prior to cocaine dosing and at various times after dosing. RESULTS: The euphoric (P = .004) and stimulating (P = .03) effects of cocaine were attenuated in a dose-dependent manner by ecopipam, while ratings of desire to take cocaine were diminished (P = .02). Ecopipam in combination with cocaine was safe and well tolerated. CONCLUSION: These data indicate a potentially important role for D1-like receptors in the acute mood-altering and rewarding effects of cocaine in humans.
Assuntos
Benzazepinas/farmacologia , Transtornos Relacionados ao Uso de Cocaína/psicologia , Cocaína/antagonistas & inibidores , Antagonistas de Dopamina/farmacologia , Euforia/efeitos dos fármacos , Adulto , Comportamento Aditivo/prevenção & controle , Comportamento Aditivo/psicologia , Benzazepinas/uso terapêutico , Cocaína/farmacologia , Transtornos Relacionados ao Uso de Cocaína/fisiopatologia , Transtornos Relacionados ao Uso de Cocaína/prevenção & controle , Antagonistas de Dopamina/uso terapêutico , Feminino , Humanos , Masculino , Receptores Dopaminérgicos/efeitos dos fármacos , Receptores Dopaminérgicos/fisiologia , RecompensaRESUMO
The efficacy and safety of risperidone long-acting injectable (RLAI) was investigated in patients in the early phases of schizophrenia and schizoaffective disorders (< or = 3 years). Patients who required a treatment change received RLAI (2-weekly gluteal injections of 25, 37.5 or 50 mg, per clinical judgement), without an oral risperidone run-in phase.A total of 382 patients were included in this 6-month open-label study; 73% of patients completed the study. A total of 84% had schizophrenia with a median duration of 1.0 year since diagnosis. Previous medications were mainly atypical antipsychotics (70%) and depot neuroleptics (24%). The main reasons for treatment change were non-compliance (42%) and insufficient efficacy (31%) of previous medication. The total Positive and Negative Syndrome Scale (PANSS) and all its subscale scores improved significantly (p < or = 0.0001), with 40% of patients showing a 20% improvement on total PANSS. Global Assessment of Functioning, quality of life, patient satisfaction and movement disorders also improved significantly. Tolerability of RLAI was generally good and no unexpected adverse events were reported. The ensured delivery of medication with RLAI resulted in significant symptom improvement in this patient population. Direct initiation of RLAI is well accepted by patients. RLAI might represent a novel option for patients in the early phases of psychosis.
Assuntos
Antipsicóticos/uso terapêutico , Transtornos Psicóticos/tratamento farmacológico , Risperidona/uso terapêutico , Esquizofrenia/tratamento farmacológico , Adulto , Idoso , Antipsicóticos/administração & dosagem , Antipsicóticos/efeitos adversos , Preparações de Ação Retardada , Discinesia Induzida por Medicamentos/epidemiologia , Feminino , Humanos , Injeções Intravenosas , Masculino , Pessoa de Meia-Idade , Satisfação do Paciente , Escalas de Graduação Psiquiátrica , Transtornos Psicóticos/psicologia , Qualidade de Vida , Risperidona/administração & dosagem , Risperidona/efeitos adversos , Psicologia do Esquizofrênico , Resultado do TratamentoRESUMO
Anxiety disorders are among the most common mental illness in the western world with a major impact on disability. But their diagnosis has lacked objective biomarkers. We previously demonstrated a human anxiety process biomarker, goal-conflict-specific electroencephalography (EEG) rhythmicity (GCSR) in the stop-signal task (SST). Here we have developed and characterized an improved test appropriate for clinical group testing. We modified the SST to produce balanced numbers of trials in clearly separated stop-signal delay groups. As previously, right frontal (F8) GCSR was extracted as the difference in EEG log Fourier power between matching stop and go trials (that is, stop-signal-specific power) of a quadratic contrast of the three delay values (that is, power when stopping and going are in balanced conflict compared with the average of when stopping or going is greater). Separate experiments assessed drug sensitivity (n=34) and personality relations (n=59). GCSR in this new SST was reduced by three chemically distinct anxiolytic drugs (administered double-blind): buspirone (10 mg), triazolam (0.25 mg) and pregabalin (75 mg); had a frequency range (4-12 Hz) consistent with rodent model data; and positively correlated significantly with neuroticism and nonsignificantly with trait anxiety scores. GCSR, measured in our new form of the SST, should be suitable as a biomarker for one specific anxiety process in the testing of clinical groups and novel drugs and in the development of measures suitable for individual diagnosis.
Assuntos
Transtornos de Ansiedade/tratamento farmacológico , Transtornos de Ansiedade/fisiopatologia , Personalidade/fisiologia , Adolescente , Adulto , Ansiolíticos/uso terapêutico , Transtornos de Ansiedade/psicologia , Biomarcadores , Encéfalo/efeitos dos fármacos , Encéfalo/fisiopatologia , Buspirona/uso terapêutico , Eletroencefalografia , Feminino , Humanos , Masculino , Pregabalina/uso terapêutico , Desempenho Psicomotor , Tempo de Reação/fisiologia , Triazolam/uso terapêutico , Adulto JovemRESUMO
This article describes a group of 10 hospitalized, mentally retarded patients with rapid cycling affective disorders, including details of demography, pattern of illness, and response to an open trial of treatment with lithium and/or carbamazepine. Family histories of these patients revealed high rates of mental illness, including affective disorder and mental retardation. Men had an earlier onset of affective illness and rapid cycling than did women. Half of the patients showed partial or complete improvement on lithium alone or in combination with carbamazepine; those who responded to the combined treatment had more episodes of affective illness per year than those who did not. Rates of response to treatment and some clinical characteristics of these patients were similar to those of non-mentally retarded rapid cycling patients.
Assuntos
Transtorno Bipolar/complicações , Deficiência Intelectual/complicações , Adulto , Transtorno Bipolar/tratamento farmacológico , Transtorno Bipolar/psicologia , Carbamazepina/administração & dosagem , Ensaios Clínicos como Assunto , Quimioterapia Combinada , Feminino , Humanos , Deficiência Intelectual/psicologia , Lítio/administração & dosagem , Carbonato de Lítio , MasculinoRESUMO
BACKGROUND: This study quantified pharmacokinetic changes in pegylated and nonpegylated interferon alfa-2b during 48 weeks of treatment and the influences of covariates on the basis of sparsely sampled serum concentrations and activity values. Possible relationships between pharmacokinetic and pharmacodynamic variables were investigated. METHODS: Patients with chronic hepatitis C were enrolled in a clinical trial that compared the efficacy of pegylated interferon alfa-2b with interferon alfa-2b. Single blood samples were obtained from each patient at weeks 4, 12, 24, 36, and 48. Three pharmacostatistical models were developed for 2 immunoassays and 1 bioassay. RESULTS: Apparent clearance values of pegylated interferon alfa-2b and interferon alfa-2b at the end of treatment declined 33.7% and 80.0%, respectively, from their week 4 values. Bioactivity increased 41% to 58% at week 48 for different treatment groups. Changes were greatest in the first weeks of administration and diminished during the subsequent months. Body weight had a modest positive effect on clearance values and activity. Within each dose level, no significant associations were observed between pharmacokinetic variables and any pharmacodynamic variables (hepatitis C virus--RNA responses or changes in neutrophils and platelets). CONCLUSIONS: This analysis confirms earlier observations of progressive pharmacokinetic changes in the patients with hepatitis C during 48 weeks of treatment. The absence of a relationship between toxicity or efficacy variables and interferon concentration or activity (within a dose level) suggests that clinical management of patients (eg, for efficacy or to manage toxicity) should be based on clinically derived dosing guidelines rather than on serum concentration or activity criteria.
Assuntos
Antivirais/farmacocinética , Hepatite C/metabolismo , Interferon-alfa , Interferon-alfa/farmacocinética , Polietilenoglicóis , Adolescente , Adulto , Idoso , Algoritmos , Antivirais/efeitos adversos , Antivirais/uso terapêutico , Plaquetas/metabolismo , Doença Crônica , Feminino , Hepatite C/tratamento farmacológico , Humanos , Interferon alfa-2 , Interferon-alfa/efeitos adversos , Interferon-alfa/uso terapêutico , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Modelos Biológicos , Neutrófilos/metabolismo , População , Proteínas RecombinantesRESUMO
AIMS: The objectives of this study were to assess the safety, pharmacokinetic and pharmacodynamic profiles, and antiviral efficacy of pegylated interferon-alpha2b monotherapy in patients with chronic hepatitis C. METHODS: Fifty-eight patients (38 men, 20 women; age range, 25 to 65 years) with compensated chronic hepatitis C were enrolled in this open-label, randomized, active controlled study. Patients received 0.035 to 2.0 microg/kg pegylated interferon-alpha2b subcutaneously weekly or the active control, interferon-alpha2b 3 million IU subcutaneously three times/week, for 24 weeks. Safety and antiviral efficacy assessments were performed during treatment and in a subsequent 4-week follow-up period. Detailed pharmacokinetic assessments were performed at weeks 1 and 4. RESULTS: Pegylated interferon-alpha2b produced dose-related reductions in white blood cells, neutrophils, and platelets, and dose-related increases in oral temperature, serum neopterin, and serum 2'5'-oligoadenylate synthetase activity, which were qualitatively similar to those produced by nonpegylated interferon-alpha2b. Reported adverse events (flu-like symptoms, asthenia) were qualitatively similar in pegylated interferon-alpha2b- and nonpegylated interferon-alpha2b-treated groups. Dose-related antiviral activity, as measured by loss of detectable serum hepatitis C virus RNA (<100 copies/mL), was noted at the end of treatment and after 4 weeks of follow-up. Both pegylated and nonpegylated interferon-alpha2b were rapidly absorbed, with maximal concentrations occurring approximately 8 to 12 hours after dose administration. Pegylated interferon-alpha2b had sustained maximal serum concentrations for 48 to 72 hours after dose administration, whereas nonpegylated interferon-alpha2b concentrations declined rapidly. Volume of distribution for both compounds was similar (approximately 1 L/kg). Pegylated interferon-alpha2b elimination half-life was approximately 10-fold greater, and mean apparent clearance was one tenth that of nonpegylated interferon-alpha2b. CONCLUSIONS: Pegylated and nonpegylated interferon-alpha2b safety and pharmacodynamic profiles were comparable. Pegylated interferon-alpha2b demonstrated delayed clearance compared with nonpegylated interferon-alpha2b, consistent with once-weekly administration.
Assuntos
Antivirais/farmacocinética , Antivirais/uso terapêutico , Hepatite C Crônica/tratamento farmacológico , Interferon-alfa/farmacocinética , Interferon-alfa/uso terapêutico , Absorção , Adulto , Idoso , Antivirais/administração & dosagem , Antivirais/química , Área Sob a Curva , Química Farmacêutica , Relação Dose-Resposta a Droga , Feminino , Hepatite C Crônica/sangue , Humanos , Injeções Subcutâneas , Interferon alfa-2 , Interferon-alfa/administração & dosagem , Interferon-alfa/química , Masculino , Pessoa de Meia-Idade , Polietilenoglicóis/química , Polietilenoglicóis/farmacologia , Reação em Cadeia da Polimerase , RNA Viral/isolamento & purificação , Proteínas Recombinantes , Resultado do TratamentoRESUMO
The effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive containing 30 micrograms ethinyl estradiol and 75 micrograms gestodene were assessed in a randomized, double-blind, placebo-controlled parallel-group study in healthy premenopausal female volunteers established in a regimen of oral contraceptive use. They received either placebo or 2400 mg/day felbamate from midcycle (day 15) to midcycle (day 14) of two consecutive oral contraceptive cycles (months 1 and 2). Pharmacokinetic assessments of ethinyl estradiol and gestodene were performed on day 14 of both cycles. To determine whether ovulation occurred, plasma progesterone and urinary luteinizing hormone levels were measured, and diaries recording vaginal bleeding were kept. Felbamate treatment resulted in a significant 42% decrease in gestodene area under the plasma concentration-time curve (0 to 24 hours) (p = 0.018) compared with baseline, whereas a minor but not clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol. There were no changes in the pharmacokinetics of ethinyl estradiol or gestodene after placebo treatment. No volunteer showed hormonal evidence of ovulation; however, one volunteer reported the onset of intermenstrual bleeding during felbamate treatment. Because of the effect of felbamate on the pharmacokinetics of gestodene and the report of intermenstrual bleeding, it is possible that the contraceptive efficacy of low-dose combination oral contraceptives may be adversely affected during felbamate treatment.
Assuntos
Anticonvulsivantes/farmacologia , Anticoncepcionais Orais Combinados/farmacocinética , Congêneres do Estradiol/farmacocinética , Etinilestradiol/farmacocinética , Norpregnenos/farmacocinética , Propilenoglicóis/farmacologia , Adulto , Anticonvulsivantes/efeitos adversos , Anticoncepcionais Orais Combinados/sangue , Método Duplo-Cego , Combinação de Medicamentos , Congêneres do Estradiol/sangue , Etinilestradiol/administração & dosagem , Etinilestradiol/sangue , Felbamato , Feminino , Humanos , Norpregnenos/administração & dosagem , Norpregnenos/sangue , FenilcarbamatosRESUMO
The effects of felbamate on the pharmacokinetics of phenobarbital and one of its main metabolites, parahydroxyphenobarbital, were assessed in a parallel-group, placebo-controlled, double-blind study, in 24 healthy volunteers. Pharmacokinetic parameters of phenobarbital and parahydroxyphenobarbital were determined from plasma and urine samples obtained after 28 days of daily administration of 100 mg phenobarbital and after a further 9 days of phenobarbital plus 2400 mg/day felbamate or placebo. Felbamate increased phenobarbital values for area under the plasma concentration-time curve from 0 to 24 hours and maximum concentration by 22% and 24%, respectively, whereas placebo had no effect. This increase was caused by a reduction in parahydroxylation of phenobarbital and possibly through effects on other metabolic pathways. Because felbamate inhibits the S-mephenytoin hydroxylase (CYP2C19) isozyme in vitro, it appears that phenobarbital hydroxylation is mediated in part by this isozyme.
Assuntos
Anticonvulsivantes/farmacologia , Anticonvulsivantes/farmacocinética , Fenobarbital/farmacocinética , Propilenoglicóis/farmacologia , Adulto , Anticonvulsivantes/administração & dosagem , Anticonvulsivantes/urina , Método Duplo-Cego , Esquema de Medicação , Interações Medicamentosas , Felbamato , Ácido Glucárico/urina , Humanos , Masculino , Fenobarbital/administração & dosagem , Fenobarbital/análogos & derivados , Fenobarbital/urina , Fenilcarbamatos , PlacebosRESUMO
This article provides an analysis of the degree of agreement between in vivo interaction studies performed in patients with epilepsy and healthy individuals, and in vitro studies which identified the cytochromes P450 (CYP) inhibited by felbamate and those involved in its metabolism. In vitro studies show that felbamate is a substrate for CYP3A4 and CYP2E1. Compounds which induce CYP3A4 (e.g. carbamazepine, phenytoin and phenobarbital) increase felbamate clearance. However, the CYP3A4 inhibitors gestodene, ethinyl estradiol and erythromycin have little or no effect on felbamate trough plasma concentrations, consistent with the fact that the pathway is relatively minor for felbamate under normal (non-induced) conditions. Felbamate has been shown in vitro to inhibit CYP2C19, which would account for its effect on phenytoin clearance, and it had been postulated that this could be the mechanism underlying the reduced clearance of phenobarbital by felbamate. Although not yet examined in vitro, felbamate appears to induce the activity of CYP3A4, which would account for it reducing plasma concentrations of carbamazepine or the progestin gestodene. Interactions involving felbamate and non-CYP450-mediated metabolic pathways have also been addressed in clinical studies. The reduction in valproic acid (valproate sodium) clearance by felbamate is through the inhibition of beta-oxidation. No clinically relevant pharmacokinetic interactions were noted between felbamate and lamotrigine, clonazepam, vigabatrin, nor the active monohydroxy metabolite of oxcarbazepine. Information on the mechanisms underlying felbamate's drug:drug interaction profile permits predictions to be made concerning the likelihood of interactions with other compounds.
Assuntos
Anticonvulsivantes/farmacocinética , Sistema Enzimático do Citocromo P-450/biossíntese , Isoenzimas/biossíntese , Fármacos Neuroprotetores/farmacocinética , Propilenoglicóis/farmacocinética , Anticonvulsivantes/administração & dosagem , Anticonvulsivantes/metabolismo , Anticonvulsivantes/farmacologia , Área Sob a Curva , Carbamazepina/farmacocinética , Inibidores das Enzimas do Citocromo P-450 , Interações Medicamentosas , Indução Enzimática/efeitos dos fármacos , Inibidores Enzimáticos/farmacocinética , Inibidores Enzimáticos/farmacologia , Epilepsia/metabolismo , Felbamato , Humanos , Técnicas In Vitro , Isoenzimas/antagonistas & inibidores , Fármacos Neuroprotetores/administração & dosagem , Fármacos Neuroprotetores/metabolismo , Fármacos Neuroprotetores/farmacologia , Fenilcarbamatos , Fenitoína/farmacocinética , Propilenoglicóis/administração & dosagem , Propilenoglicóis/metabolismo , Propilenoglicóis/farmacologia , Ácido Valproico/farmacocinéticaRESUMO
1. The major toxicity associated with oral therapy with ribavirin is anaemia, which has been postulated to occur as a result of accumulation of ribavirin triphosphate interfering with erythrocyte respiration. The objective of this study was to determine the mechanism by which ribavirin enters into erythrocytes. 2. Entry into human erythrocytes was examined by measuring influx rates of [3H]-ribavirin alone and with the inhibitor nitrobenzylthioinosine (NBMPR), and by investigating the inhibitory effects of nucleoside and nucleobase permeants on ribavirin transport, by use of inhibitor oil-stop methods. Transport mechanisms were further characterized by assessment of substrates to cause countertransport of ribavirin in preloaded erythrocytes, and by measuring the effects of ribavirin on [3H]-NBMPR binding to erythrocyte membranes. 3. Human erythrocytes had a saturable influx mechanism for ribavirin (Km at 22 degrees C of 440+/-100 microM) which was inhibited by nanomolar concentrations of NBMPR (IC50 0.99+/-0.15 nM). Nucleosides also inhibited the influx of ribavirin (adenosine more effective than uridine) but the nucleobases hypoxanthine and adenine had no effect. In addition, uridine caused the countertransport of ribavirin in human erythrocytes. Entry of ribavirin into horse erythrocytes, a cell type that lacks the NBMPR-sensitive (es) nucleoside transporter, proceeded slowly and via a pathway that was resistant to NBMPR inhibition. Ribavirin was a competitive inhibitor of adenosine influx (mean Ki 0.48+/-0.14 mM) and also inhibited NBMPR binding to erythrocyte membranes (mean Ki 2.2+/-0.39 mM). 4. These data indicate that ribavirin is a transported permeant for the es nucleoside transporter of human erythrocytes. There was no evidence for ribavirin entering cells via a nucleobase transporter.
Assuntos
Antivirais/sangue , Proteínas de Transporte/metabolismo , Transportador Equilibrativo 2 de Nucleosídeo , Eritrócitos/metabolismo , Proteínas de Membrana/metabolismo , Ribavirina/sangue , Adenosina/metabolismo , Animais , Membrana Eritrocítica/metabolismo , Cavalos , Humanos , Técnicas In Vitro , Tioinosina/análogos & derivados , Tioinosina/metabolismo , Uridina/sangueRESUMO
To examine the role of alpha 2-adrenoceptors in the control of cortisol and ACTH, hormone responses to the selective alpha 2-antagonist idazoxan were studied in 12 normal volunteers. Plasma cortisol and ACTH were measured from 0930h-1230h on three occasions: before, on the 1st day, and on the 22nd day of an open treatment trial with idazoxan 40 mg administered three times per day. Compared with pretreatment cortisol levels, acute but not chronic idazoxan treatment attenuated the normal diurnal fall in plasma cortisol. Plasma ACTH concentrations were not altered by either dose of idazoxan. The attenuation of the diurnal fall in cortisol after acute idazoxan may be mediated through increased central availability of norepinephrine, and is similar to responses after high doses of the less selective alpha 2-antagonist yohimbine. Activity of central noradrenergic neurons appears to be reduced or normalized by chronic idazoxan, indicated by restoration of the normal diurnal fall in cortisol.
Assuntos
Antagonistas Adrenérgicos alfa/farmacologia , Hormônio Adrenocorticotrópico/sangue , Dioxanos/farmacologia , Hidrocortisona/sangue , Receptores Adrenérgicos/efeitos dos fármacos , Adulto , Ritmo Circadiano/efeitos dos fármacos , Ritmo Circadiano/fisiologia , Humanos , Idazoxano , Masculino , Receptores Adrenérgicos/fisiologiaRESUMO
A paradigm for assessing benzodiazepine receptor sensitivity was developed using intravenous midazolam in normal volunteers. After administration of incremental doses of midazolam, alterations in saccadic eye movement parameters and psychological self ratings were assessed. Significant changes included dose-dependent slowing of peak velocity, peak acceleration, peak deceleration, reduced saccade acceleration/deceleration ratio and saccade accuracy, and increased sedation self-ratings. Changes in saccade variables and sedation ratings were significantly correlated, and also correlated with plasma midazolam concentrations. No significant changes were seen in saccade latency or anxiety self-ratings. Pharmacological specificity of these changes was demonstrated by their reversal with the benzodiazepine antagonist flumazenil. This challenge paradigm appears to be a sensitive means of assessing benzodiazepine receptor function in man.
Assuntos
Flumazenil/farmacologia , Midazolam/farmacologia , Receptores de GABA-A/efeitos dos fármacos , Movimentos Sacádicos/efeitos dos fármacos , Adulto , Relação Dose-Resposta a Droga , Eletroculografia/efeitos dos fármacos , Feminino , Humanos , Hipnóticos e Sedativos/farmacologia , Masculino , Midazolam/antagonistas & inibidores , Midazolam/sangueRESUMO
The effects of lithium on psychomotor performance were examined in six healthy male volunteers (aged 26-31 years) and compared with those of a similar control population. Three computerised psychomotor tests (serial reaction time, semantic reasoning and syntatic reasoning) were administered before lithium, after 5 and 22 days of lithium carbonate (800 mg/d) and 4 days and 1 month after stopping the lithium. The only significant effect was an impairment of semantic reasoning during the chronic (22 day) test. This suggests a selective effect of lithium on associative mental tasks and may explain the subjects' experience of slowing in recall of object names whilst taking lithium.
Assuntos
Cognição/efeitos dos fármacos , Lítio/farmacologia , Adulto , Humanos , Masculino , Tempo de Reação/efeitos dos fármacos , Semântica , Pensamento/efeitos dos fármacos , Comportamento Verbal/efeitos dos fármacosRESUMO
The effects of alpha 2-adrenoceptor agonists and antagonists on saccadic eye movements were studied in normal volunteers using the agonist clonidine and the antagonist idazoxan. Changes in blood pressure, heart rate, and several psychological self-ratings were also recorded. Clonidine produced marked slowing of peak saccade velocity, acceleration and deceleration, with deceleration affected more than acceleration, but had no effect on saccade error or latency measurements. In contrast, most saccade parameters were not altered by idazoxan, although fatigue effects were eliminated. Blood pressure, heart rate, and self ratings of alertness were increased by idazoxan and reduced by clonidine, with opposite effects noted on sedation self-ratings. There were no correlations between the clonidine-induced changes in saccade parameters and changes in self-ratings. Although the slowing of some saccade parameters by clonidine may imply that alpha 2-adrenoceptors are involved in control of saccades, it may also be due to sedation. Although alpha 2-adrenoceptor antagonists may abolish fatigue effects, they cannot increase them over baseline values.